Curis Stock Price, News & Analysis (NASDAQ:CRIS)

$0.90 0.01 (1.12 %)
(As of 11/24/2017 06:30 AM ET)
Previous Close$0.89
Today's Range$0.87 - $0.90
52-Week Range$0.86 - $3.48
Volume872,719 shs
Average Volume1.74 million shs
Market Capitalization$146.47 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86

About Curis (NASDAQ:CRIS)

Curis logoCuris, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.

Receive CRIS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CRIS
CUSIP23126910
Phone617-503-6500

Debt

Debt-to-Equity Ratio1.24%
Current Ratio5.15%
Quick Ratio5.15%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.53 million
Price / Sales19.60
Cash FlowN/A
Price / CashN/A
Book Value$0.19 per share
Price / Book4.74

Profitability

Trailing EPS($0.40)
Net Income$-60,410,000.00
Net Margins-629.29%
Return on Equity-250.58%
Return on Assets-81.57%

Miscellaneous

Employees58
Outstanding Shares163,980,000

Frequently Asked Questions for Curis (NASDAQ:CRIS)

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) posted its quarterly earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.02. The biotechnology company had revenue of $2.44 million for the quarter, compared to analyst estimates of $2.19 million. Curis had a negative net margin of 629.29% and a negative return on equity of 250.58%. The firm's quarterly revenue was up 38.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.21) earnings per share. View Curis' Earnings History.

Where is Curis' stock going? Where will Curis' stock price be in 2017?

3 analysts have issued 1 year price targets for Curis' shares. Their forecasts range from $6.00 to $7.00. On average, they expect Curis' share price to reach $6.50 in the next year. View Analyst Ratings for Curis.

What are Wall Street analysts saying about Curis stock?

Here are some recent quotes from research analysts about Curis stock:

  • 1. According to Zacks Investment Research, "Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. " (11/10/2017)
  • 2. Cowen Inc analysts commented, "In our view, recent underperformance of CRIS shares is not reflective of the continued." (5/5/2017)

Who are some of Curis' key competitors?

Who are Curis' key executives?

Curis' management team includes the folowing people:

  • James R. McNab Jr., Independent Chairman of the Board (Age 73)
  • Ali Fattaey Ph.D., President, Chief Executive Officer, Director (Age 52)
  • James E. Dentzer, Chief Financial Officer, Chief Administrative Officer (Age 50)
  • David Tuck M.D., Chief Medical Officer (Age 65)
  • Lori A. Kunkel M.D., Director (Age 59)
  • Martyn D. Greenacre, Independent Director (Age 75)
  • Robert E. Martell M.D., Ph.D., Independent Director (Age 54)
  • Kenneth J. Pienta M.D., Independent Director (Age 57)
  • Marc Rubin M.D., Independent Director (Age 62)

Who owns Curis stock?

Curis' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include First Eagle Investment Management LLC (16.18%), JPMorgan Chase & Co. (1.45%) and FNY Partners Fund LP (0.04%). Company insiders that own Curis stock include Ali PhD Fattaey, Daniel R Passeri, Discovery Technologie Aurigene, James R Mcnab, Kenneth I Kaitin, Marc Rubin and Martyn D Greenacre. View Institutional Ownership Trends for Curis.

Who bought Curis stock? Who is buying Curis stock?

Curis' stock was bought by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC, JPMorgan Chase & Co. and FNY Partners Fund LP. Company insiders that have bought Curis stock in the last two years include Ali PhD Fattaey, Discovery Technologie Aurigene and Marc Rubin. View Insider Buying and Selling for Curis.

How do I buy Curis stock?

Shares of Curis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Curis' stock price today?

One share of Curis stock can currently be purchased for approximately $0.90.

How big of a company is Curis?

Curis has a market capitalization of $146.47 million and generates $7.53 million in revenue each year. The biotechnology company earns $-60,410,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Curis employs 58 workers across the globe.

How can I contact Curis?

Curis' mailing address is 4 MAGUIRE ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected]


MarketBeat Community Rating for Curis (CRIS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  215 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  357
MarketBeat's community ratings are surveys of what our community members think about Curis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Curis (NASDAQ:CRIS)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.252.382.563.00
Ratings Breakdown: 3 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.75$6.75$5.60$5.60
Price Target Upside: 448.78% upside329.94% upside223.70% upside193.19% upside

Consensus Price Target History for Curis (NASDAQ:CRIS)

Price Target History for Curis (NASDAQ:CRIS)

Analysts' Ratings History for Curis (NASDAQ:CRIS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/23/2017GuggenheimInitiated CoverageBuy$7.00N/AView Rating Details
5/15/2017Cowen IncReiterated RatingBuyN/AView Rating Details
3/11/2017FBR & CoSet Price TargetBuy$6.00LowView Rating Details
10/12/2016Royal Bank Of CanadaSet Price TargetBuy$7.00N/AView Rating Details
9/7/2016Robert W. BairdReiterated RatingOutperform$7.00N/AView Rating Details
3/1/2016SunTrust Banks, Inc.Initiated CoverageBuy$3.00N/AView Rating Details
2/29/2016Roth CapitalReiterated RatingBuy$5.00N/AView Rating Details
(Data available from 11/25/2015 forward)

Earnings

Earnings History and Estimates Chart for Curis (NASDAQ:CRIS)

Earnings by Quarter for Curis (NASDAQ:CRIS)

Earnings History by Quarter for Curis (NASDAQ CRIS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.09)($0.11)$2.19 million$2.44 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.09)($0.10)$2.08 million$2.10 millionViewListenView Earnings Details
5/4/2017Q1 17($0.09)($0.11)$1.98 million$2.13 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.10)($0.08)$1.97 million$2.40 millionViewListenView Earnings Details
11/3/2016Q316($0.10)($0.21)$1.84 million$1.80 millionViewListenView Earnings Details
8/4/2016Q216($0.09)($0.09)$2.05 million$1.70 millionViewListenView Earnings Details
5/9/2016Q116($0.08)($0.07)$2.30 million$1.70 millionViewListenView Earnings Details
2/29/2016Q415($0.12)($0.10)$2.98 million$2.10 millionViewListenView Earnings Details
11/9/2015Q315($0.08)($0.04)$2.82 million$2.00 millionViewN/AView Earnings Details
8/6/2015Q215($0.06)($0.06)$3.50 million$2.10 millionViewN/AView Earnings Details
5/7/2015Q115($0.06)($0.07)$2.27 million$1.17 millionViewN/AView Earnings Details
2/24/2015Q4 14($0.07)($0.07)$2.69 million$2.00 millionViewN/AView Earnings Details
11/10/2014Q314($0.05)($0.06)$4.13 million$1.80 millionViewN/AView Earnings Details
8/7/2014Q214($0.06)($0.02)$3.46 million$4.80 millionViewN/AView Earnings Details
5/8/2014Q114($0.07)($0.06)$1.88 million$1.30 millionViewN/AView Earnings Details
2/20/2014Q413($0.08)($0.05)$1.59 million$1.52 millionViewN/AView Earnings Details
11/5/2013Q313($0.01)($0.02)$6.44 million$7.20 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.05)($0.02)$4.43 million$5.40 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.05)($0.06)$3.86 million$0.90 millionViewN/AView Earnings Details
2/20/2013Q4 2012($0.08)($0.15)$2.07 million$1.69 millionViewN/AView Earnings Details
11/6/2012Q312($0.08)($0.04)$1.01 million$0.60 millionViewN/AView Earnings Details
8/2/2012($0.05)($0.04)ViewN/AView Earnings Details
5/8/2012$0.02$0.03ViewN/AView Earnings Details
10/27/2011($0.07)($0.05)ViewN/AView Earnings Details
7/28/2011($0.07)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Curis (NASDAQ:CRIS)
2017 EPS Consensus Estimate: ($0.30)
2018 EPS Consensus Estimate: ($0.31)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.08)($0.08)($0.08)
Q2 20171($0.07)($0.07)($0.07)
Q3 20171($0.07)($0.07)($0.07)
Q4 20171($0.08)($0.08)($0.08)
Q1 20181($0.07)($0.07)($0.07)
Q2 20181($0.08)($0.08)($0.08)
Q3 20181($0.08)($0.08)($0.08)
Q4 20181($0.08)($0.08)($0.08)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Curis (NASDAQ:CRIS)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Curis (NASDAQ CRIS)

Insider Ownership Percentage: 4.07%
Institutional Ownership Percentage: 46.88%
Insider Trades by Quarter for Curis (NASDAQ:CRIS)
Insider Trades by Quarter for Curis (NASDAQ:CRIS)

Insider Trades by Quarter for Curis (NASDAQ CRIS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/16/2017Marc RubinDirectorBuy25,000$0.98$24,500.00View SEC Filing  
11/15/2017Ali Ph.D. FattaeyCEOBuy50,000$1.06$53,000.00View SEC Filing  
5/5/2017James R McnabDirectorSell76,276$2.04$155,603.04View SEC Filing  
5/2/2017James R McnabDirectorSell116,708$2.38$277,765.04View SEC Filing  
4/27/2017James R McnabDirectorSell146,694$2.61$382,871.34View SEC Filing  
4/24/2017James R McnabDirectorSell110,322$2.59$285,733.98View SEC Filing  
9/7/2016Discovery Technologie AurigeneMajor ShareholderBuy10,208,333$2.40$24,499,999.20View SEC Filing  
5/27/2016Martyn D GreenacreDirectorSell15,000$1.69$25,350.00View SEC Filing  
5/26/2016Kenneth I KaitinDirectorSell15,000$1.76$26,400.00View SEC Filing  
12/30/2015Daniel R. PasseriDirectorSell14,400$3.01$43,344.00View SEC Filing  
12/29/2015Daniel R. PasseriDirectorSell11,200$2.91$32,592.00View SEC Filing  
12/28/2015Daniel R. PasseriDirectorSell13,600$2.85$38,760.00View SEC Filing  
12/23/2015Daniel R. PasseriDirectorSell48,900$2.78$135,942.00View SEC Filing  
12/21/2015Daniel R. PasseriDirectorSell289,000$2.99$864,110.00View SEC Filing  
8/27/2014Ali Ph.D. FattaeyCEOBuy62,890$1.60$100,624.00View SEC Filing  
12/11/2013Ali Ph.D. FattaeyCOOBuy3,000$2.52$7,560.00View SEC Filing  
11/12/2013Michael GrayCFOBuy10,000$2.86$28,600.00View SEC Filing  
11/8/2013Kenneth PientaDirectorBuy20,000$2.95$59,000.00View SEC Filing  
8/16/2013James McnabDirectorSell50,000$4.00$200,000.00View SEC Filing  
12/6/2012Daniel R PasseriCEOBuy25,000$3.03$75,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Curis (NASDAQ CRIS)

Source:
DateHeadline
Should You Be Concerned About Curis Inc’s (CRIS) Investors?Should You Be Concerned About Curis Inc’s (CRIS) Investors?
finance.yahoo.com - November 24 at 4:02 PM
ETFs with exposure to Curis, Inc. : November 20, 2017ETFs with exposure to Curis, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 6:32 PM
Curis, Inc. (CRIS) Given Consensus Rating of "Hold" by BrokeragesCuris, Inc. (CRIS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 20 at 3:58 AM
Curis, Inc. (CRIS) Expected to Announce Quarterly Sales of $2.03 MillionCuris, Inc. (CRIS) Expected to Announce Quarterly Sales of $2.03 Million
www.americanbankingnews.com - November 18 at 3:02 AM
 Brokerages Expect Curis, Inc. (CRIS) to Post -$0.09 Earnings Per Share Brokerages Expect Curis, Inc. (CRIS) to Post -$0.09 Earnings Per Share
www.americanbankingnews.com - November 16 at 7:08 PM
Insider Buying: Curis, Inc. (CRIS) Director Purchases 25,000 Shares of StockInsider Buying: Curis, Inc. (CRIS) Director Purchases 25,000 Shares of Stock
www.americanbankingnews.com - November 16 at 5:12 PM
Ali Ph.D. Fattaey Purchases 50,000 Shares of Curis, Inc. (CRIS) StockAli Ph.D. Fattaey Purchases 50,000 Shares of Curis, Inc. (CRIS) Stock
www.americanbankingnews.com - November 15 at 1:30 PM
3 Things In Biotech You Should Learn Today: November 13, 20173 Things In Biotech You Should Learn Today: November 13, 2017
seekingalpha.com - November 14 at 2:19 AM
Curis, Inc. (CRIS) Downgraded by Zacks Investment Research to "Sell"Curis, Inc. (CRIS) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - November 11 at 7:38 PM
Curis, Inc. :CRIS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017Curis, Inc. :CRIS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 10 at 5:25 PM
SunTrust Banks Comments on Curis, Inc.s FY2017 Earnings (CRIS)SunTrust Banks Comments on Curis, Inc.'s FY2017 Earnings (CRIS)
www.americanbankingnews.com - November 10 at 7:47 AM
Curis, Inc. (CRIS) Forecasted to Post FY2021 Earnings of ($0.11) Per ShareCuris, Inc. (CRIS) Forecasted to Post FY2021 Earnings of ($0.11) Per Share
www.americanbankingnews.com - November 9 at 4:34 PM
ETFs with exposure to Curis, Inc. : November 8, 2017ETFs with exposure to Curis, Inc. : November 8, 2017
finance.yahoo.com - November 8 at 10:37 PM
Curis, Inc. (CRIS) Posts  Earnings Results, Misses Estimates By $0.02 EPSCuris, Inc. (CRIS) Posts Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - November 8 at 3:02 PM
Curis Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Curis Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 8 at 4:40 AM
Curis, Inc. to Host Earnings CallCuris, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 11:38 PM
Curis Reports Third Quarter 2017 Financial ResultsCuris Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 11:38 PM
Curis reports 3Q lossCuris reports 3Q loss
finance.yahoo.com - November 7 at 11:38 PM
What Does Curis Inc’s (CRIS) Share Price Indicate?What Does Curis Inc’s (CRIS) Share Price Indicate?
finance.yahoo.com - November 7 at 11:38 PM
Edited Transcript of CRIS earnings conference call or presentation 7-Nov-17 1:30pm GMTEdited Transcript of CRIS earnings conference call or presentation 7-Nov-17 1:30pm GMT
finance.yahoo.com - November 7 at 11:38 PM
Curis, Upcoming SITC Meeting, Aurigene Collaboration and Analysts ReviewCuris, Upcoming SITC Meeting, Aurigene Collaboration and Analysts Review
finance.yahoo.com - November 6 at 6:48 PM
Curis to Present at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT SummitCuris to Present at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit
feeds.benzinga.com - November 3 at 7:28 AM
What You Must Know About Curis Inc’s (CRIS) Financial StrengthWhat You Must Know About Curis Inc’s (CRIS) Financial Strength
finance.yahoo.com - November 1 at 6:25 PM
Curis to Release Third Quarter 2017 Financial Results and Hold Conference Call on November 7, 2017Curis to Release Third Quarter 2017 Financial Results and Hold Conference Call on November 7, 2017
feeds.benzinga.com - November 1 at 7:47 AM
Head-To-Head Review: Curis (CRIS) & Its PeersHead-To-Head Review: Curis (CRIS) & Its Peers
www.americanbankingnews.com - November 1 at 5:06 AM
Comparing Curis (CRIS) and Its RivalsComparing Curis (CRIS) and Its Rivals
www.americanbankingnews.com - October 31 at 10:00 AM
Curis, Inc. (CRIS) Receives Average Recommendation of "Hold" from BrokeragesCuris, Inc. (CRIS) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 26 at 3:32 AM
Curis, Inc. (CRIS) to Release Quarterly Earnings on WednesdayCuris, Inc. (CRIS) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 6:52 AM
Curis, Inc. (CRIS) Coverage Initiated by Analysts at GuggenheimCuris, Inc. (CRIS) Coverage Initiated by Analysts at Guggenheim
www.americanbankingnews.com - October 23 at 6:20 PM
Curis, Inc. (CRIS) Upgraded by Zacks Investment Research to HoldCuris, Inc. (CRIS) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - October 16 at 8:10 PM
Zacks: Analysts Anticipate Curis, Inc. (CRIS) Will Post Quarterly Sales of $2.17 MillionZacks: Analysts Anticipate Curis, Inc. (CRIS) Will Post Quarterly Sales of $2.17 Million
www.americanbankingnews.com - October 10 at 8:51 AM
 Analysts Expect Curis, Inc. (CRIS) to Post -$0.09 EPS Analysts Expect Curis, Inc. (CRIS) to Post -$0.09 EPS
www.americanbankingnews.com - October 8 at 10:28 AM
Arsanis Announces Appointments of Chip Clark and David McGirr to Board of Directors and Promotion of Michael Gray to Chief Operating Officer and Chief Financial OfficerArsanis Announces Appointments of Chip Clark and David McGirr to Board of Directors and Promotion of Michael Gray to Chief Operating Officer and Chief Financial Officer
www.businesswire.com - October 4 at 11:41 AM
Curis, Inc. (CRIS) Given Consensus Recommendation of "Hold" by AnalystsCuris, Inc. (CRIS) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - October 1 at 2:50 AM
Curis to Present at the Cantor Fitzgerald Global Healthcare Conference - GlobeNewswire (press release)Curis to Present at the Cantor Fitzgerald Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 23 at 2:38 AM
Curis to Present at the Cantor Fitzgerald Global Healthcare ConferenceCuris to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 22 at 4:32 PM
Comparing Curis (CRIS) & Idera Pharmaceuticals (IDRA)Comparing Curis (CRIS) & Idera Pharmaceuticals (IDRA)
www.americanbankingnews.com - September 21 at 4:48 AM
Curis, Inc. (CRIS) Expected to Announce Quarterly Sales of $2.17 MillionCuris, Inc. (CRIS) Expected to Announce Quarterly Sales of $2.17 Million
www.americanbankingnews.com - September 21 at 3:18 AM
Curis, Inc. (CRIS) Expected to Post Earnings of -$0.09 Per ShareCuris, Inc. (CRIS) Expected to Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - September 19 at 4:24 PM
Why Curis Inc (CRIS) Could Be A BuyWhy Curis Inc (CRIS) Could Be A Buy
finance.yahoo.com - September 18 at 10:31 PM
Curis Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)Curis Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)
www.globenewswire.com - September 15 at 10:58 PM
Curis Announces Pricing of Public Offering of Common StockCuris Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 14 at 6:20 PM
Curis prices stock offering but doesnt disclose priceCuris prices stock offering but doesn't disclose price
seekingalpha.com - September 14 at 9:25 AM
3 Things In Biotech You Should Learn Today: September 13, 20173 Things In Biotech You Should Learn Today: September 13, 2017
seekingalpha.com - September 14 at 5:11 AM
Curis Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)Curis Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - September 13 at 6:48 PM
Curis Announces Proposed Public Offering of Common StockCuris Announces Proposed Public Offering of Common Stock
finance.yahoo.com - September 13 at 6:47 PM
Aurigene, a Wholly Owned Subsidiary of Dr. Reddy’s, and Curis Announce CA-170 Program Update Following Data Presented at ESMO 2017Aurigene, a Wholly Owned Subsidiary of Dr. Reddy’s, and Curis Announce CA-170 Program Update Following Data Presented at ESMO 2017
finance.yahoo.com - September 12 at 6:13 PM
Curis (CRIS) & Aurigene Report CA-170 Program Update Following ... - StreetInsider.comCuris (CRIS) & Aurigene Report CA-170 Program Update Following ... - StreetInsider.com
www.streetinsider.com - September 11 at 6:11 PM
Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017
finance.yahoo.com - September 11 at 6:11 PM
Curis (CRIS) Presents At Bairds 2017 Global Healthcare Conference - SlideshowCuris (CRIS) Presents At Baird's 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - September 7 at 5:39 PM

Social Media

Financials

Chart

Curis (NASDAQ CRIS) Chart for Saturday, November, 25, 2017
Loading chart…

This page was last updated on 11/25/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.